List view / Grid view
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
Using rodent models, the researchers emphasized the potential of newly generated neurons in adulthood to serve as therapy for addressing the functional deficits and pathology associated with Alzheimer's disease.
Researchers from the University of Illinois have identified a new class of ribosomally synthesised and post-translationally modified peptides (RiPPs) named "daptides" that have haemolytic activity.
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
The team are the first researchers in the world to successfully create an organoid containing both heart muscle cells and cells of the outer layer of the heart wall.
The researchers identified 1,068 transposable element-derived transcripts with the potential to produce tumour antigens that could serve as targets for new immunotherapies.
Oregon State University researchers have developed a screening model for rapid testing of multiple drug compounds, using a 3D cellular platform.
The new findings could pave the way to safer aspirin alternatives and might also have implications for improving cancer immunotherapies.
UW researchers at the Carbone Cancer Center have identified the cells that can cause graft versus host disease, the most common complication of bone marrow transplants.
In this article, Drug Target Review's Ria Kakkad and Izzy Wood explore the results of the latest research on lab automation techniques and technologies designed to accelerate drug discovery.
In an ongoing discovery programme, a chemical-creation platform is being revealed – based on cubic molecules – that could help breathe new life into tired drugs.
The researchers found that cancer cells with thicker glycocalyx barrier are better at evading immune cells.
The scientists from Texas A&M have developed GTX-102, a novel therapeutic candidate to target Angelman syndrome by reactivating expression of deficient protein.
The finding is an critical first step towards classifying lesions on the pancreas that are at highest risk of becoming cancerous, enabling their removal before they start to spread.
